Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
GV-58
80
CHF
CHF 80.00
In stock
AG-MR-C0035-M0011 mgCHF 80.00
AG-MR-C0035-M0055 mgCHF 320.00
| Product Details | |
|---|---|
| Synonyms | (2R)-2-[(6-{[(5-Methylthiophen-2-yl)methyl]amino}-9-propyl-9H-purin-2-yl)amino]butan-1-ol; Rx-ID: 23159892 |
| Product Type | Chemical |
| Properties | |
| Formula |
C18H26N6OS |
| MW | 374.5 |
| CAS | 1402821-41-3 |
| Purity Chemicals | ≥97% (NMR) |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO or ethanol. |
| Reconstitution | Stock solutions can be made up to 10mM in DMSO. |
| Identity | Determined by 1H-NMR. |
| InChi Key | DPTXJOUVBMUSGY-CYBMUJFWSA-N |
| Smiles | CCCN1C=NC2=C(NCC3=CC=C(C)S3)N=C(N[C@H](CC)CO)N=C12 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
Keep cool and dry. Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Selective N- and P/Q-type Ca2+-channel agonist. These Ca2+-channels regulate transmitter release in synapses.
- Potential lead compound for a variety of disorders that result in neuromuscular weakness.
Product References
- Synthesis and biological evaluation of a selective N- and P/Q-type Calcium channel agonist: M. Liang, et al.; ACS Med. Chem. Lett. 3, 985 (2012)
- New calcium channel agonists as potential therapeutics in Lambert-Eaton myasthenic syndrome and other neuromuscular diseases: T.B. Tarr, et al.; Ann. N. Y. Acad. Sci. 1275, 85 (2012)
- Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome: T.B. Tarr, et al.; J. Neurosci. 33, 10559 (2013)
- Complete reversal of Lambert–Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist: T.B. Tarr, et al.; J. Physiol. 3687, 592 (2014)
- Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome: T.B. Tarr, et al.; Mol. Neurobiol. 52, 456 (2015)
- The Calcium Channel Subunit Alpha2delta2 Suppresses Axon Regeneration in the Adult CNS: A. Tedeschi, et al.; Neuron 92, 419 (2016)
- New Cav2 calcium channel gating modifiers with agonist activity and therapeutic potential to treat neuromuscular disease: M. Wu, et al.; Neuropharmacology 131, 176 (2018)
- R-Roscovitine Improves Motoneuron Function in Mouse Models for Spinal Muscular Atrophy: R. Tejero, et al.; iSci. 23, 100826 (2020)
Related Products
